Correspondence 0001140361-24-020628 from Aquestive Therapeutics, Inc. (AQST) (CIK 0001398733) (AQST)
Aquestive Therapeutics, Inc. (AQST) (CIK 0001398733)
Date: April 19, 2024 · CIK: 0001398733 · Accession: 0001140361-24-020628
AI Filing Summary & Sentiment
File numbers found in text: 333-278498
Letter
Office of Life Sciences Division of Corporation Finance United States Securities and Exchange Commission Attention: Withdrawal of Request for Acceleration of Effectiveness Aquestive Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-278498
Dear Ms. Sheppard,
Aquestive Therapeutics, Inc. (the “Company”) hereby respectfully withdraws its request for the acceleration of the effectiveness of the Company’s Registration Statement on Form S-3, File No. 333-278498 (the “Registration Statement”) to April 19, 2024, at 9:00 a.m., Eastern Time, previously delivered to you on April 16, 2024. The Company will file a separate request for the acceleration of the effectiveness of the Registration Statement at a future date and time.
Please contact our legal counsel, Anna Tomczyk, of Dechert LLP, at (212) 641-5626, if you have any questions concerning this request and to confirm that our request for withdrawal has been accepted by the Securities and Exchange Commission.
Sincerely,
AQUESTIVE THERAPEUTICS, INC.
Show Raw Text
CORRESP
1
filename1.htm
April 19, 2024
Office of Life Sciences
Division of Corporation Finance
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention:
Tamika N. Sheppard
Re:
Withdrawal of Request for Acceleration of Effectiveness
Aquestive Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-278498
Dear Ms. Sheppard,
Aquestive Therapeutics, Inc. (the “Company”) hereby respectfully withdraws its request for the acceleration of the effectiveness of the Company’s Registration
Statement on Form S-3, File No. 333-278498 (the “Registration Statement”) to April 19, 2024, at 9:00 a.m., Eastern Time, previously delivered to you on April 16, 2024. The Company will file a separate request
for the acceleration of the effectiveness of the Registration Statement at a future date and time.
Please contact our legal counsel, Anna Tomczyk, of Dechert LLP, at (212) 641-5626, if you have any questions concerning this request and to confirm that our request for withdrawal has been accepted by
the Securities and Exchange Commission.
Sincerely,
AQUESTIVE THERAPEUTICS, INC.
/s/ Lori J. Braender
Lori J. Braender
Senior Vice President, General Counsel,
Chief Compliance Officer & Corporate Secretary
cc:
David S. Rosenthal, Dechert LLP
Anna Tomczyk, Dechert LLP